Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Cellular Strategies of Protein Quality Control-Degradation

CellularPQCD

Maintaining the quality of all proteins in an organism is fundamental to life since it ensures tissue function, organismal health, and longevity. Protein quality control (PQC) is achieved by selective degradation of damaged proteins, limiting the formation of protein aggregates and neurodegeneration characteristic of Alzheimers, Huntingtons, and...

Funding Programme
Start Date
End Date
Total Funding
€ 2 500 000
European Countries Involved

Center for Artificial Intelligence and Quantum Computing in System Brain Research

CLARA

CLARA, the Center for Artificial Intelligence and Quantum Computing in System Brain Research, represents the interdisciplinary center of excellence focused on the next generation of artificial intelligence/machine learning applications and quantum-centric supercomputing tools to push the frontier of neurodegeneration research, particularly...

Funding Programme
Start Date
End Date
Total Funding
€ 14 999 782
European Countries Involved

Common mechanisms and pathways in Stroke and Alzheimer's disease.

CoSTREAM

Common mechanisms and pathways in Stroke and Alzheimer's disease. It has long been recognized that stroke and (Alzheimer’s Disease) AD often co-occur and have an overlapping pathogenesis. As such, these two diseases are not considered fellow travelers, but rather partners in crime. This multidisciplinary consortium includes epidemiologists...

Funding Programme
Start Date
End Date
Total Funding
€ 5 100 373
European Countries Involved

COMORBIDITY MECHANISMS UTILIZED IN HEALTHCARE

COMMUTE

The COVID pandemic can be seen as an experiment done with the entirety of humankind (as almost everybody has been or will get infected with SARS-CoV-2). It will therefore have the best coverage over the widest variation possible and is therefore ideally suited to study the effects of infections with SARS-CoV-2 on large quantities of heterogeneous...

Funding Programme
Start Date
End Date
Total Funding
€ 7 280 986

COnfident DEcisions

CODE

Virtually every decision people make comes with a sense of confidence – a subjective estimate of decision quality. The human capacity for confidence has tremendous social, clinical, and industrial impact. For example, children who can correctly judge their own level of confidence perform better academically. In the elderly, confidence declines...

Funding Programme
Start Date
End Date
Total Funding
€ 2 446 322
European Countries Involved

Connecting to the Networks of the Human Brain

ConnectToBrain

ConnectToBrain will introduce whole-brain multi-locus transcranial magnetic stimulation (mTMS), in which the brain-stimulating electric-field location, direction, magnitude and timing are controlled electronically based on real-time high-density electroencephalography (hdEEG) information of activity and connectivity in brain networks. The final...

Funding Programme
Start Date
End Date
Total Funding
€ 9 981 794
European Countries Involved

Consortium on Health and Ageing: Network of Cohorts in Europe and the United States

CHANCES

CHANCES aims at combining and integrating on-going cohort studies in order to produce evidence on ageing-related health characteristics and determinants in Europe, and their socio-economic implications. 15 cohorts participate, covering populations from 18 EU Member States, 4 associate countries, and 3 additional countries. The combination of these...

Funding Programme
Start Date
End Date
Total Funding
€ 15 410 903

Control of amyloid formation via beta-hairpin molecular recognition features

BETACONTROL

The aggregation of proteins into amyloid fibrils is involved in various diseases which place a high burden on patients, families, caregivers, and healthcare systems, including Alzheimer’s disease, Parkinson’s disease and type 2 diabetes. While the therapeutic potential of the inhibition of amyloid formation and spreading has been recognized, there...

Funding Programme
Start Date
End Date
Total Funding
€ 1 920 697
European Countries Involved

Coordination Action in support of the implementation of a Joint Programming Initiative for Combating Neurodegenerative Diseases, in particular Alzheimer’s disease

JUMPAHEAD

The objective of the Coordination Action JUMPAHEAD is to support the implementation of the pilot Joint Programming Initiative on combating neurodegenerative diseases, in particular Alzheimer’s disease (JPND). Neurodegenerative disorders are incurable and debilitating conditions that result in progressive degeneration or death of nerve cells. Of...

Funding Programme
Start Date
End Date
Total Funding
€ 2 618 090

Critical solutions for elderly well-being

RISE-WELL

Mental health and emotional well-being during old age (60\) should be regarded as important as at any other time of a persons’ life. Older people are more likely to experience events that affect emotional well-being, such as bereavement or disability. Unfortunately, mental health problems are under identified in older people, whom themselves are...

Funding Programme
Start Date
End Date
Total Funding
€ 2 691 279
European Countries Involved

Deciphering Interactions of Acquired Risk Factors and ApoE-mediated Pathways in Alzheimer’s Disease

DACAPO-AD

Alzheimer’s disease (AD) imposes an enormous personal burden on patients and caregivers, as well as a tremendous socio-economic impact on society. However, there is a paucity of pharmaceutical or interventional strategies that have a proven impact on the incidence or progression of AD. One reason is that most models are based on familial (early...

Funding Programme
Start Date
End Date
Total Funding
€ 1 594 408
European Countries Involved

Deep Brain Neuromodulation using Temporal Interference Magnetic Stimulation

TIMS

Five out of ten diseases leading to long term-disability are related to the brain, including stroke, depression or dementia. Despite tremendous progress in neurotechnology, there is still no effective treatment option available for many brain-related disorders. A very promising approach to treat brain disorders uses transcranial electric or...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).